Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by COLLINS, A.J.
Right arrow Articles by DIXON, A. ST.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by COLLINS, A.J.
Right arrow Articles by DIXON, A. ST.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1988 British Society for Rheumatology

brief-report

A PROSPECTIVE ENDOSCOPIC STUDY OF THE EFFECT OF ORUDIS AND ORUVAIL ON THE UPPER GASTROINTESTINAL TRACT, IN PATIENTS WITH OSTEOARTHRITIS

A.J. COLLINS1,2,3, JOAN DAVIS2 and A. ST.J. DIXON1,2

1Royal National Hospital for Rheumatic Diseases Bath BA1 1RL, UK
2Pharmacology Group, University of Bath

Correspondence to: 3Address correspondence to Dr. A. J. Collins, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath BA1 1RL, UK.

The effect of ketoprofen, a nonsteroidal anti-inflammatory drug, was tested on the upper gastrointestinal tract (UGIT) in patients with osteoarthritis. The drug was given in two forms; as simple ketoprofen (Orudis) and as a slow release preparation (Oruvail), when the drug was not released into the stomach, but into the small intestine. These formulations were compared with indomethacin for endoscopically proven damage to the UGIT.

Orudis and Oruvail produced similar damage to previously normal UGITs over 56 days; each formulation produced about a 50% incidence of ulceration and inflammation. Indomethacin, by comparison produced less damage. The results suggested that the direct action of ketoprofen (barrier breaking effect) adds little to the mechanism of gastric cytotoxicity of this drug, which may be assumed to be predominantly caused by a systemic effect of ketoprofen on gastric cytoprotective mechanisms.

KEY WORDS: Ketoprofen, Orudis, Oruvail, Endoscopy, Upper gastrointestinal tract, Cytoprotection.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.